• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

370
60
44
42
20

COUNTRY

41
9
5
5
4

PRICE

136
413
509
1,026

PUBLISHED

16
60
287
1,026

PRODUCT TYPE

993
17
11
4
1

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Osteoarthritis Pain - Pipeline Review, H1 2014

Osteoarthritis Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Osteoarthritis Pain - Pipeline Review, H1 2014’, provides an overview of the Osteoarthritis Pain’s therapeutic pipeline. This...

February 2014
FROM

Neuropathic Pain - Pipeline Review, H1 2014

Neuropathic Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Neuropathic Pain - Pipeline Review, H1 2014’, provides an overview of the Neuropathic Pain’s therapeutic pipeline. This...

February 2014
FROM

Substance (Drug) Abuse - Pipeline Review, H1 2014

Substance (Drug) Abuse - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Substance (Drug) Abuse - Pipeline Review, H1 2014’, provides an overview of the Substance (Drug) Abuse’s therapeutic...

February 2014
FROM

Epilepsy - Pipeline Review, H1 2014

Epilepsy - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H1 2014’, provides an overview of the Epilepsy’s therapeutic pipeline. This report provides comprehensive...

February 2014
FROM

Inflammatory Pain - Pipeline Review, H1 2014

Inflammatory Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Inflammatory Pain - Pipeline Review, H1 2014’, provides an overview of the Inflammatory Pain’s therapeutic pipeline. This...

February 2014
FROM

Huntington's Disease - Pipeline Review, H1 2014

Huntington's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Huntington's Disease - Pipeline Review, H1 2014’, provides an overview of the Huntington's Disease’s therapeutic pipeline. This...

February 2014
FROM

Drug Addiction - Pipeline Review, H1 2014

Drug Addiction - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Drug Addiction - Pipeline Review, H1 2014’, provides an overview of the Drug Addiction’s therapeutic pipeline. This report...

February 2014
FROM

Stroke - Pipeline Review, H1 2014

Stroke - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Stroke - Pipeline Review, H1 2014’, provides an overview of the Stroke’s therapeutic pipeline. This report provides comprehensive...

February 2014
FROM

Acute Pain - Pipeline Review, H1 2014

Acute Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H1 2014’, provides an overview of the Acute Pain’s therapeutic pipeline. This report provides...

February 2014
FROM

Major Depressive Disorder - Pipeline Review, H1 2014

Major Depressive Disorder - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2014’, provides an overview of the Major Depressive Disorder’s...

February 2014
FROM

Equine Encephalitis - Pipeline Review, H1 2014

Equine Encephalitis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Equine Encephalitis - Pipeline Review, H1 2014’, provides an overview of the Equine Encephalitis’s therapeutic pipeline. This...

February 2014
FROM

Alzheimer's Disease - Pipeline Review, H1 2014

Alzheimer's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This...

February 2014
FROM

Schizophrenia - Pipeline Review, H1 2014

Schizophrenia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Schizophrenia - Pipeline Review, H1 2014’, provides an overview of the Schizophrenia’s therapeutic pipeline. This report...

February 2014
FROM

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014’, provides an overview of the Amyotrophic Lateral...

February 2014
FROM

Psychosis - Pipeline Review, H1 2014

Psychosis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Psychosis - Pipeline Review, H1 2014’, provides an overview of the Psychosis’s therapeutic pipeline. This report provides comprehensive...

February 2014
FROM

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core...

February 2014
FROM

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms,...

February 2014
FROM
Loading Indicator

Our Clients

Our clients' logos